Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three tesla

Investigative Radiology

Volumn 43, Issue 10, 2008, Pages 745-751

  Stanwell, Peter ^a,b   Russell, Peter ^a,c   Carter, Jonathan ^c   Pather, Selvan ^c   Heintze, Sebastian ^c   Mountford, Carolyn ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

3 Tesla; Magnetic resonance spectroscopy; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID; SIALIC ACID;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; CYSTADENOMA; DIAGNOSTIC IMAGING; ENDOMETRIUM TUMOR; FEMALE; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMAGE QUALITY; IMAGING SYSTEM; LAPAROTOMY; METABOLITE; OVARY CARCINOMA; OVARY TUMOR; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL NOISE RATIO; TERATOMA; TUMOR DIAGNOSIS; FEASIBILITY STUDY; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY;

ADULT; AGED; AGED, 80 AND OVER; FEASIBILITY STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 58149385902     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31817e9104     Document Type: Article

References (46)

1. Boyle P, Maisonneuve P, Autier P. Update on cancer control in women. Int J Gynaecol Obstet. 2000;70:263-303.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137-2150.
3. Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108(3 pt 1):521-528.
4. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma, peritoneal carcinoma. In: VT De Vita, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams and Wilkins; 2001:1597-1632.
5. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107:1399-1410.
6. Oei AL, Massuger LF, Bulten J, et al. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer. 2006;94:814-819.
7. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999;49:297-320.
8. Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: a meta-analysis. Radiology. 2000;217:803-811.
9. Funt SA, Hann LE. Detection and characterization of adnexal masses. Radiol Clin North Am. 2002;40:591-608.
10. Kinkel K, Lu Y, Mehdizade A, et al. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization - meta-analysis and Bayesian analysis. Radiology. 2005;236:85-94.
11. Sohaib SA, Mills TD, Sahdev A, et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol. 2005;60:340-348.
12. Woodward PJ, Hosseinzadeh K, Saenger JS. From the archives of the AFIP: radiologic staging of ovarian carcinoma with pathologic correlation. Radiographics. 2004;24:225-246.
13. Heijmink SW, Scheenen TW, Fütterer JJ, et al. Prostate and lymph node proton magnetic resonance (MR) spectroscopic imaging with external array coils at 3 T to detect recurrent prostate cancer after radiation therapy. Invest Radiol. 2007;42:420-427.
14. Mountford C, Lean C, Malycha P, et al. Proton spectroscopy provides accurate pathology on biopsy and in vivo. J Magn Reson Imaging. 2006;24:459-477.
15. Mountford CE, Doran S, Lean CL, et al. Proton MRS can determine the pathology of human cancers with a high level of accuracy. Chem Rev. 2004; 104:3677-3704.
16. Smith IC, Blandford DE. Diagnosis of cancer in humans by 1H NMR of tissue biopsies. Biochem Cell Biol. 1998. 76:472-476.
17. Mackinnon WB, Russell P, May GL, et al. Characterization of human ovarian epithelial tumors (ex vivo) by proton magnetic resonance spectroscopy. Int J Gynecol Cancer. 1995;5:211-221.
18. Wallace JC, Raaphorst GP, Somorjai RL, et al. Classification of 1H MR spectra of biopsies from untreated and recurrent ovarian cancer using linear discriminant analysis. Magn Reson Med. 1997;38:569-576.
19. Massuger LF, van Vierzen PB, Engelke U, et al. lH-magnetic resonance spectroscopy: a new technique to discriminate benign from malignant ovarian tumors. Cancer. 1998;82:1726-1730.
20. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-A pilot study at 4 T. Radiology. 2004;233:424-431.
21. Kumar M, Jagannathan NR, Seenu V, et al. Monitoring the therapeutic response of locally advanced breast cancer patients: Sequential in vivo proton MR spectroscopy study. J Magn Reson Imaging. 2006;24:325-332.
22. Stanwell P, Mountford C. In vivo proton MR spectroscopy of the breast. Radiographics. 2007;27(suppl 1):S253-S266.
23. Griswold MA, Jakob PM, Heidemann RM, et al. Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med. 2002;47:1202-1210.
24. Hennig J, Scheffler K. Hyperechoes. Magn Reson Med. 2001;46:6-12.
25. Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333-348.
26. Okada T, Harada M, Matsuzaki K, et al. Evaluation of female intrapelvic tumors by clinical proton MR spectroscopy. J Magn Reson Imaging. 2001;13:912-917.
27. Hascalik S, Celik O, Sarac K, et al. Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest. 2005;60:121-127.
28. Ogg RJ, Kingsley RB, Taylor JS. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. J Magn Reson B. 1994; 104:1-10.
29. Delikatny EJ, Hull WE, Mountford CE. The effect of altering time domains and window functions in two-dimensional proton COSY spectra of biological specimens. J Magn Reson. 1991. 94:463-473.
30. Bezabeh T, Smith IC, Krupnik E, et al. Diagnostic potential for cancer via 1H magnetic resonance spectroscopy of colon tissue. Anticancer Res. 1996;16:1553-1558.
31. King AD, Yeung DK, Ahuja AT, et al. In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol. 2005;54:l 12 - 117.
32. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 1997;204:661-666.
33. Mackinnon WB, Huschtscha L, Dent K, et al. Correlation of cellular differentiation in human colorectal carcinoma and adenoma cell lines with metabolite profiles determined by 1H magnetic resonance spectroscopy. Int J Cancer. 1994;59:248-261.
34. Russell P, Robboy SJ, Anderson MC eds. Ovarian tumors: classification and clinical perspectives. Pathology of the Female Reproductive Tract. Philadelphia, PA: Churchill Livingstone; 2002:527-538.
35. Mahon MM, Williams AD, Soutter WP, et al. 1H magnetic resonance spectroscopy of invasive cervical cancer: an in vivo study with ex vivo corroboration. NMR Biomed. 2004; 17:1-9.
36. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004; 64:4270-4276.
37. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996; 16:1375 - 1380.
38. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst. 2002;94:1197-1203.
39. Katz-Brull R, Seger D, Rivenson-Segal D, et al. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether- phospholipid synthesis. Cancer Res. 2002;62:1966-1970.
40. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia. 2000;2:166-189.
41. Barker PB, Gillard JH, van Zijl PC, et al. Acute stroke: evaluation with serial proton magnetic resonance spectroscopic imaging. Radiology. 1994; 192:723-732.
42. Adalsteinsson E, Spielman DM, Pauly JM, et al. Feasibility study of lactate imaging of head and neck tumors. NMR Biomed. 1998; 11:360-369.
43. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med. 2003;49:223-232.
44. Tate AR, Majós C, Moreno A, et al. Automated classification of short echo time in in vivo 1H brain tumor spectra: a multicenter study. Magn Reson Med. 2003;49:29-36.
45. Boss EA, Moolenaar SH, Massuger LF, et al. High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid. NMR Biomed. 2000; 13:297-305.
46. Mun CW, Cho JY, Shin WJ, et al. Ex vivo proton MR spectroscopy (1H-MRS) for evaluation of human gastric carcinoma. Magn Reson Imaging. 2004;22:861-870.